智通财经APP获悉，三叶草生物-B(02197)再涨超7%，截至发稿，涨5.21%，报3.03港元，成交额3064.97万港元。
消息面上，三叶草生物此前公告，评估集团自研专有的呼吸道联合疫苗候选产品SCB-1022(RSV+hMPV)及SCB-1033(RSV+hMPV+PIV3)的澳洲II期临床试验已完成受试者招募。初步临床结果预计于2026年第三季度公布。
此外，三叶草生物近期与全球疫苗免疫联盟达成和解。根据和解安排，公司需支付700万美元一次性前期付款，并按约定承担每半年递延付款、与未来现金收入挂钩的或有付款，整体付款总额上限为数千万美元中段水平，较Gavi此前索偿的2.24亿美元大幅缩减。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.